Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2012-11-08 Earnings Release
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its first quarter fiscal year 2013 results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is only 2651 characters, which is quite short and consistent with a brief announcement rather than a full financial report. According to the rules, a Form 8-K announcing quarterly results and including a press release is best classified as an Earnings Release (ER), since it is the initial announcement of quarterly financial results with key highlights only, not a full interim report (IR).
2012-11-08 English
NOTICE AND PROXY STATEMENT
Proxy Solicitation & Information Statement
2012-10-25 English
PRIMARY DOCUMENT
Director's Dealing
2012-10-09 English
PRIMARY DOCUMENT
Director's Dealing
2012-10-03 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PRELIMINARY PROXY STATEMENT' and references SEC Schedule 14A, which is used for proxy statements filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The content includes details about the Annual Meeting, voting instructions, election of directors, executive compensation, and other proposals to be voted on by shareholders. It is a solicitation of proxies for the Annual Meeting, not the actual voting results or the meeting minutes. The document is comprehensive and over 15,000 characters, indicating it is the full proxy statement, not a brief announcement or a report publication notice. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2012-10-02 English
FORM 10-K
Annual Report FY 2012
2012-09-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.